Canaccord upgraded Genomic Health to Buy and increased its price target to $44 from $26 on shares. Analyst Mark Massaro's proprietary survey with urologists and doctors indicate favorable brand awareness of Genomic Health's (GHDX) prostate test over Myriad Genetics' (MYGN) and 56% of the physicians survey indicated they are likely or highly likely to order Genomic Health's test in 2016 versus 48% for Myriad's. Massaro believes the risk/reward for shares is now favorable following Genomic Health's Medicare reimbursement decision for its prostate test in October and increased visibility for prostate test growth.